AbbVie has inked a landmark deal worth $700 million upfront with IGI Therapeutics for exclusive rights to ISB-2001, a trispecific antibody targeting BCMA, CD38, and CD3, showing promise in treating relapsed or refractory multiple myeloma. The drug has received orphan drug and fast track designations by the FDA and is currently in early Phase 1 clinical evaluation. Early results indicate a favorable safety profile alongside a high response rate in a heavily pretreated patient population. The agreement includes potential milestone payments exceeding $1.2 billion and tiered royalties, with commercial rights spanning North America, Europe, Japan, and China; Glenmark Pharmaceuticals retains rights in emerging markets. This acquisition aligns with AbbVie's strategic expansion into multi-target antibody therapies for oncology and autoimmune diseases.